meta
|
Preg
- medecines during pregnancy KB
Search
Valproate (Epilepsy)
Overall results
Study description
Excluded studies
Table
Graphic
auto
during pregnancy (anytime or not specified)
1st trimester
2nd trimester
3rd trimester
2nd and/or 3rd trimester
throughout pregnancy
early pregnancy
days before delivery
late pregnancy
preconception-only
periconceptional
preconceptional for kinetic reason
at least 1st trimester
3 months (or more) before pregnancy or during pregnancy
1st and 2nd trimester
3 months or more before pregnancy or1st trimester
Whatever the period exposition
individual studies
Outcome
TE
95% CI
n cases
n exposed
k
Pub. bias
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)
Jäger-Roman (Valproate), 1986 Robert (Valproate), 1986 D'Souza (Valproate) (Controls unexposed, sick), 1991 Samrén (Valproate), 1999 Kaneko (Valproate), 1999 Canger (Valproate), 1999 Hvas (Valproate) (Controls unexposed, sick), 2000 Dean (Valproate), 2002 Kaaja (Valproate), 2003 Endo (Valproate) (Controls unexposed, sick), 2004 Artama (Valproate), 2005 Viinikainen (Valproate) (Controls unexposed, sick) a, 2006 Mawer (Valproate) (Controls unexposed, sick), 2010 Bànhidy (Valproate), 2011 Charlton (Valproate) (Controls unexposed, sick), 2011 Hernández-Díaz (Valproate) (Controls unexposed, disease free), 2012 Arteaga-Vázquez (Valproate), 2012 Cassina (Valproate) (Controls unexposed, disease free), 2013 Campbell (Valproate) (Controls unexposed, sick), 2014 Veiby (Valproate) (Controls unexposed, sick), 2014 Vanya (Valproate) (Controls unexposed, sick), 2015 Petersen (Valproate) (Controls unexposed, sick), 2017 Tomson (Valproate), 2018 Putignano (Valproate), 2019 Huber-Mollema (Valproate), 2019 Vajda (Valproate) (Controls unexposed, sick), 2019 Aydin (Valproate) (Controls unexposed, sick), 2020 Thomas (Valproate) (Controls unexposed, sick), 2021 Hosny (Valproate) (Controls unexposed, sick), 2021
29
3.36
[
2.79
; 4.06]
1,017
5,201
low
Major congenital malformations
Jäger-Roman (Valproate), 1986 Robert (Valproate), 1986 Canger (Valproate), 1999 Samrén (Valproate), 1999 Hvas (Valproate) (Controls unexposed, sick), 2000 Dean (Valproate), 2002 Kaaja (Valproate), 2003 Viinikainen (Valproate) (Controls unexposed, sick) a, 2006 Mawer (Valproate) (Controls unexposed, sick), 2010 Bànhidy (Valproate), 2011 Charlton (Valproate) (Controls unexposed, sick), 2011 Hernández-Díaz (Valproate) (Controls unexposed, disease free), 2012 Cassina (Valproate) (Controls unexposed, disease free), 2013 Campbell (Valproate) (Controls unexposed, sick), 2014 Veiby (Valproate) (Controls unexposed, sick), 2014 Vanya (Valproate) (Controls unexposed, sick), 2015 Petersen (Valproate) (Controls unexposed, sick), 2017 Tomson (Valproate), 2018 Vajda (Valproate) (Controls unexposed, sick), 2019 Huber-Mollema (Valproate), 2019 Thomas (Valproate) (Controls unexposed, sick), 2021 Hosny (Valproate) (Controls unexposed, sick), 2021
22
3.24
[
2.56
; 4.10]
833
4,753
low
Congenital heart defects
D'Souza (Valproate) (Controls unexposed, sick), 1991 Canger (Valproate), 1999 Artama (Valproate), 2005 Mawer (Valproate) (Controls unexposed, sick), 2010 Bànhidy (Valproate), 2011 Hernández-Díaz (Valproate) (Controls exposed to Lamotrigine, sick), 2012 Vajda (Valproate) (Controls unexposed, sick), 2013 Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 Tomson (Valproate), 2018 Thomas (Valproate) (Controls unexposed, sick), 2021
10
3.30
[
2.11
; 5.17]
144
3,902
low
Limb defects
Artama (Valproate), 2005 Mawer (Valproate) (Controls unexposed, sick), 2010 Vajda (Valproate) (Controls unexposed, sick), 2013 De Jonge (Valproate), 2013 Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 Thomas (Valproate) (Controls unexposed, sick), 2021
6
3.77
[
1.96
; 7.24]
226
2,183
not evaluable
Neural Tube Defects
Canger (Valproate), 1999 Mawer (Valproate) (Controls unexposed, sick), 2010 Bànhidy (Valproate), 2011 Hernández-Díaz (Valproate) (Controls exposed to Lamotrigine, sick), 2012 Vajda (Valproate) (Controls unexposed, sick), 2013 Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 Tomson (Valproate), 2018
7
9.34
[
4.08
; 21.40]
52
3,298
not evaluable
Hypospadias
D'Souza (Valproate) (Controls unexposed, sick), 1991 Bànhidy (Valproate), 2011 Hernández-Díaz (Valproate) (Controls exposed to Lamotrigine, sick), 2012 Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 Tomson (Valproate), 2018
5
4.64
[
2.00
; 10.77]
64
2,933
not evaluable
Spina bifida
Czeizel (Valproate), 1992 Artama (Valproate), 2005 Viinikainen (Valproate) (Controls unexposed, sick) a, 2006 Charlton (Valproate) (Controls unexposed, sick), 2011
4
9.14
[
2.63
; 31.73]
14
518
not evaluable
Microcephaly / Small head circumference for gestational age
Dravet (Valproate), 1992 Battino (Valproate), 1999 Díaz-Romero (Valproate), 1999 Kini (Valproate) (Controls unexposed, sick), 2006 Pennell (Valproate), 2012
5
1.31
[
0.63
; 2.74]
34
199
not evaluable
Polydactyly
D'Souza (Valproate) (Controls unexposed, sick), 1991 Viinikainen (Valproate) (Controls unexposed, sick) a, 2006 Bànhidy (Valproate), 2011 Tomson (Valproate), 2018
4
4.37
[
0.52
; 36.93]
10
1,415
not evaluable
Oro-facial clefts
Hernández-Díaz (Valproate) (Controls exposed to Lamotrigine, sick), 2012 De Jonge (Valproate), 2013 Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 Tomson (Valproate), 2018
4
3.90
[
1.69
; 9.03]
329
2,989
not evaluable
Urinary malformations
Artama (Valproate), 2005 Tomson (Valproate), 2018 Thomas (Valproate) (Controls unexposed, sick), 2021
3
1.16
[
0.46
; 2.92]
26
1,985
not evaluable
Digestive system anomalies
Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 Thomas (Valproate) (Controls unexposed, sick), 2021
2
1.31
[
0.50
; 3.46]
16
1,561
not evaluable
Minor congenital malformations
Robert (Valproate), 1986 Battino (Valproate), 1992 Dean (Valproate), 2002
3
5.11
[
2.13
; 12.25]
43
83
not evaluable
Nervous system anomalies
De Jonge (Valproate), 2013 Thomas (Valproate) (Controls unexposed, sick), 2021
2
13.76
[
4.97
; 38.10]
211
372
not evaluable
Cleft lip with or without cleft palate
Artama (Valproate), 2005 Viinikainen (Valproate) (Controls unexposed, sick) a, 2006
2
7.19
[
1.57
; 32.82]
7
291
not evaluable
Craniosynostosis
D'Souza (Valproate) (Controls unexposed, sick), 1991
1
15.00
[
0.12
; 1923.88]
-
1
not evaluable
Down syndrom / Trisomy 21
D'Souza (Valproate) (Controls unexposed, sick), 1991
1
15.00
[
0.12
; 1923.88]
-
1
not evaluable
Eye defects
Dean (Valproate), 2002 Artama (Valproate), 2005
2
0.45
[
0.12
; 1.72]
10
309
not evaluable
Genital anomalies
Artama (Valproate), 2005 De Jonge (Valproate), 2013
2
3.07
[
0.98
; 9.59]
324
298
not evaluable
Hip dislocation and/or dysplasia
D'Souza (Valproate) (Controls unexposed, sick), 1991
1
15.00
[
0.12
; 1923.88]
-
1
not evaluable
Valproate syndrome
0
-
-
-
-
-
Chromosomal abnormalities
Artama (Valproate), 2005
1
10.77
[
0.44
; 265.09]
1
263
not evaluable
Cleft palate
Viinikainen (Valproate) (Controls unexposed, sick) a, 2006
1
1.87
[
0.04
; 96.99]
-
28
not evaluable
Ear, face and neck anomalies
Artama (Valproate), 2005
1
0.71
[
0.03
; 14.91]
2
263
not evaluable
Growth parameters and prematurity
Preterm (< 37 weeks)
Jäger-Roman (Valproate), 1986 Endo (Valproate) (Controls unexposed, sick), 2004 McVearry (Valproate), 2009 Nadebaum (Valproate), 2011 Cummings (Valproate) (Controls unexposed, disease free), 2011 Pennell (Valproate), 2012 Veiby (Valproate) (Controls unexposed, sick) b, 2013 Artama (Valproate) (Controls unexposed, sick), 2013 Arkilo (Valproate), 2015 Cohen (Valproate) (Controls unexposed NOS), 2019 Putignano (Valproate), 2019 Coste (Valproate) (Controls unexposed, NOS), 2020 Aydin (Valproate) (Controls unexposed, sick), 2020
13
1.19
[
1.01
; 1.41]
252,163
2,049
low
Small for gestational age (weight)
Endo (Valproate) (Controls unexposed, sick), 2004 Burja (Valproate) (Controls unexposed, sick), 2006 Pennell (Valproate), 2012 Artama (Valproate) (Controls unexposed, sick), 2013 Veiby (Valproate) (Controls unexposed, sick) b, 2013 Putignano (Valproate), 2019 Cohen (Valproate) (Controls unexposed NOS), 2019 Coste (Valproate) (Controls unexposed, NOS), 2020 Aydin (Valproate) (Controls unexposed, sick), 2020 Dreier (Valproate), 2021
10
1.34
[
0.97
; 1.85]
209,368
3,888
low
Low birth weight (< 2500g)
Kini (Valproate) (Controls unexposed, sick), 2006 Artama (Valproate) (Controls unexposed, sick), 2013 Veiby (Valproate) (Controls unexposed, sick) b, 2013 Coste (Valproate) (Controls unexposed, NOS), 2020
4
1.35
[
0.92
; 2.00]
91,672
1,797
not evaluable
Large for gestational age (weight)
Artama (Valproate) (Controls unexposed, sick), 2013 Putignano (Valproate), 2019 Aydin (Valproate) (Controls unexposed, sick), 2020
3
1.21
[
0.74
; 1.98]
158
845
not evaluable
Macrosomia (> 4000g)
Endo (Valproate) (Controls unexposed, sick), 2004 Kini (Valproate) (Controls unexposed, sick), 2006 Coste (Valproate) (Controls unexposed, NOS), 2020
3
0.91
[
0.55
; 1.51]
577,407
1,059
not evaluable
Very preterm (28 to 32 weeks)
Coste (Valproate) (Controls unexposed, NOS), 2020
1
1.21
[
0.54
; 2.70]
8,590
991
not evaluable
Extremely preterm (< 28 weeks)
Coste (Valproate) (Controls unexposed, NOS), 2020
1
0.85
[
0.12
; 6.01]
2,042
991
not evaluable
Large head circumference for gestational age
Díaz-Romero (Valproate), 1999
1
0.79
[
0.01
; 44.65]
-
10
not evaluable
Maternal consequences
Caesarean
Endo (Valproate) (Controls unexposed, sick), 2004 Borthen (Valproate) (Controls unexposed, sick), 2010 Artama (Valproate) (Controls unexposed, sick), 2013
3
0.93
[
0.76
; 1.14]
831
926
not evaluable
Preeclampsia
Borthen (Valproate) (Controls unexposed, sick), 2011 Pennell (Valproate), 2012 Cohen (Valproate) (Controls unexposed NOS), 2019 Aydin (Valproate) (Controls unexposed, sick), 2020
4
1.41
[
0.84
; 2.37]
53,647
91
not evaluable
Assisted deliveries (forceps, vacuum, ...)
Endo (Valproate) (Controls unexposed, sick), 2004 Borthen (Valproate) (Controls unexposed, sick), 2010
2
1.18
[
0.73
; 1.90]
177
220
not evaluable
Gestational diabetes
McVearry (Valproate), 2009 Pennell (Valproate), 2012 Aydin (Valproate) (Controls unexposed, sick), 2020
3
0.62
[
0.13
; 2.89]
9
81
not evaluable
Postpartum hemorrhage
Borthen (Valproate) (Controls unexposed, sick), 2010
1
1.44
[
1.01
; 2.06]
319
215
not evaluable
Abruptio placentae (retroplacental hematoma)
Cohen (Valproate) (Controls unexposed NOS), 2019
1
0.63
[
0.19
; 2.09]
20,260
-
not evaluable
Amniotic fluid problems (polyhydramnios and/or oligohydramnios)
Aydin (Valproate) (Controls unexposed, sick), 2020
1
2.05
[
0.04
; 110.56]
-
11
not evaluable
Polyhydramnios
Endo (Valproate) (Controls unexposed, sick), 2004
1
0.11
[
0.00
; 14.76]
-
5
not evaluable
Maternal consequences (as a whole)
Alsfouk (Valproate), 2022
1
2.86
[
0.52
; 15.77]
8
12
not evaluable
Neonatal disorders
Low Apgar score (< 7) (at 5 min)
Borthen (Valproate) (Controls unexposed, sick), 2010 Pennell (Valproate), 2012 Veiby (Valproate) (Controls unexposed, sick) b, 2013 Artama (Valproate) (Controls unexposed, sick), 2013 Putignano (Valproate), 2019
5
1.78
[
0.92
; 3.45]
63
683
not evaluable
Neonatal medical care
D'Souza (Valproate) (Controls unexposed, sick), 1991 Viinikainen (Valproate) (Controls unexposed, disease free) a, 2006 Artama (Valproate) (Controls unexposed, sick), 2013 Putignano (Valproate), 2019 Aydin (Valproate) (Controls unexposed, sick), 2020
5
2.01
[
1.54
; 2.62]
2,092
771
not evaluable
Low Apgar score (< 7) (at 1 min)
Endo (Valproate) (Controls unexposed, sick), 2004 Pennell (Valproate), 2012 Artama (Valproate) (Controls unexposed, sick), 2013
3
2.54
[
0.71
; 9.05]
132
667
not evaluable
Feeding difficulty
D'Souza (Valproate) (Controls unexposed, sick), 1991 Burja (Valproate) (Controls unexposed, sick), 2006
2
24.38
[
1.49
; 397.73]
2
3
not evaluable
Neonatal disorders (as a whole)
D'Souza (Valproate) (Controls unexposed, sick), 1991 Coste (Valproate) (Controls unexposed, NOS), 2020
2
0.92
[
0.76
; 1.11]
222,323
992
not evaluable
Neonatal intracranial hemorrhage
D'Souza (Valproate) (Controls unexposed, sick), 1991 Burja (Valproate) (Controls unexposed, sick), 2006
2
15.00
[
1.09
; 206.94]
3
3
not evaluable
Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation
Burja (Valproate) (Controls unexposed, sick), 2006
1
Out of scale
189.00
[
2.70
; 13229.55]
1
2
not evaluable
Fetal distress
McVearry (Valproate), 2009
1
0.09
[
0.00
; 1.83]
4
16
not evaluable
Jaundice
D'Souza (Valproate) (Controls unexposed, sick), 1991
1
4.33
[
0.06
; 320.42]
1
1
not evaluable
Neonatal hypotonia
D'Souza (Valproate) (Controls unexposed, sick), 1991
1
15.00
[
0.12
; 1923.88]
-
1
not evaluable
Neonatal infections
D'Souza (Valproate) (Controls unexposed, sick), 1991
1
15.00
[
0.12
; 1923.88]
-
1
not evaluable
Neonatal tachypnea
D'Souza (Valproate) (Controls unexposed, sick), 1991
1
15.00
[
0.12
; 1923.88]
-
1
not evaluable
Very low Apgar score (< 5) (at 1 min)
0
-
-
-
-
-
Long term consequences
Behavioral disorders
Veiby (Valproate) (Controls unexposed, sick) b, 2013 Cohen (Valproate), 2013 Bromley (Valproate), 2016 Huber-Mollema (Valproate), 2019 Dreier (Valproate) (Epilepsy) (Controls unexposed, sick), 2023
5
0.93
[
0.65
; 1.34]
151
2,088
not evaluable
Emotional disorders
Cohen (Valproate), 2013 Bromley (Valproate), 2016 Huber-Mollema (Valproate), 2019 Dreier (Valproate) (Epilepsy) (Controls unexposed, sick), 2023
4
0.97
[
0.77
; 1.22]
591
2,069
not evaluable
Child/Infant death (> 28 days of life)
Artama (Valproate) (Controls unexposed, sick), 2013 Coste (Valproate) (Controls unexposed, NOS), 2020
2
3.01
[
1.62
; 5.60]
4,714
1,694
not evaluable
Child/Infant growth abnormalities (> 1 year)
Pennell (Valproate), 2012
1
0.24
[
0.03
; 2.07]
7
44
not evaluable
Child/Infant head circumference abnormalities (> 1 year)
Pennell (Valproate), 2012
1
1.39
[
0.03
; 71.26]
-
42
not evaluable
Child/Infant lenght abnormalities (> 1 year)
Kini (Valproate) (Controls unexposed, sick), 2006
1
2.55
[
0.69
; 9.43]
10
63
not evaluable
Child/Infant weight abnormalities (> 1 year)
Kini (Valproate) (Controls unexposed, sick), 2006
1
1.16
[
0.35
; 3.82]
12
63
not evaluable
Intrauterine deaths
Intrauterine deaths (as a whole or unspecified)
Meador (Valproate), 2006 Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 Tomson (Valproate), 2015 Arkilo (Valproate), 2015 Miškov (Valproate) (Controls unexposed, sick), 2016 Vajda (Valproate) (Controls unexposed, sick), 2018 Trivedi (Valproate) (Controls unexposed, sick), 2018
7
1.46
[
1.01
; 2.11]
468
3,144
not evaluable
Early intrauterine death (< 22 weeks)
Babic (Valproate), 2014 Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 Tomson (Valproate), 2015 Arkilo (Valproate), 2015 Miškov (Valproate) (Controls unexposed, sick), 2016
5
1.04
[
0.84
; 1.29]
366
2,475
not evaluable
Late intrauterine deaths (> 22 weeks)
Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 Arkilo (Valproate), 2015 Tomson (Valproate), 2015 Aydin (Valproate) (Controls unexposed, sick), 2020 AlSheikh (Valproate) (Controls unexposed, sick), 2020
5
1.83
[
1.01
; 3.31]
42
2,475
not evaluable
Elective/induced termination of pregnancy
Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014 Miškov (Valproate) (Controls unexposed, sick), 2016 Hosny (Valproate) (Controls unexposed, sick), 2021
3
1.83
[
0.80
; 4.17]
21
1,304
not evaluable
Perinatal death
Canger (Valproate), 1999 Artama (Valproate) (Controls unexposed, sick), 2013 Tomson (Valproate), 2015
3
2.16
[
0.95
; 4.89]
27
1,833
not evaluable
Therapeutic terminations of pregnancy
Miškov (Valproate) (Controls unexposed, sick), 2016
1
0.64
[
0.01
; 40.08]
-
6
not evaluable
Ectopic pregnancy
Campbell (Valproate) (Controls exposed to Lamotrigine, sick), 2014
1
1.70
[
0.03
; 85.94]
-
1,290
not evaluable
Neuro-developmental disorders
Language disorders/delay
Adab (Valproate), 2004 Gaily (Valproate) (Controls unexposed, sick), 2004 Eriksson (Valproate), 2005 Shallcross (Valproate), 2011 Nadebaum (Valproate), 2011 Meador (Valproate), 2013 Baker (Valproate) (Controls unexposed, sick), 2015 Videman (Valproate) (Controls unexposed, disease free), 2016 Bromley (Valproate), 2016 Deshmukh (Valproate), 2016 Kasradze (Valproate) (Controls unexposed, disease free), 2017 Husebye (Valproate) (Controls unexposed, sick), 2020 Coste (Valproate) (Controls unexposed, NOS), 2020 Thomas (Valproate), 2022
14
3.02
[
2.10
; 4.36]
72,249
1,394
critical
Cognitive developmental disorders/delay (> 6 years old)
Adab (Valproate), 2004 Gaily (Valproate) (Controls unexposed, sick), 2004 Vinten (Valproate), 2005 Viinikainen (Valproate) b, 2006 Titze (Valproate) (Controls unexposed, sick), 2008 Nadebaum (Valproate), 2011 Meador (Valproate), 2013 Baker (Valproate) (Controls unexposed, sick), 2015 Bromley (Valproate), 2016 Thomas (Valproate), 2022 Dreier (Valproate) (Epilepsy) (Controls unexposed, sick), 2023
11
2.59
[
1.90
; 3.51]
308
2,266
low
ASD (Autism spectrum disorder): Diagnosis/Risk
Adab (Valproate), 2004 Bromley (Valproate) (Controls unexposed, sick), 2013 Wood (Valproate), 2015 Bjørk (Valproate) (Controls unexposed, sick), 2018 Huber-Mollema (Valproate), 2019 Coste (Valproate) (Controls unexposed, NOS), 2020 Wiggs (Valproate), 2020 Dreier (Valproate) (Epilepsy) (Controls unexposed, sick), 2023
8
2.71
[
2.08
; 3.52]
4,756
3,135
not evaluable
Neuro-developmental disorders (as a whole)
Katz (Valproate), 2001 Adab (Valproate), 2004 Viinikainen (Valproate) b, 2006 Dean (Valproate) (Controls unexposed, sick), 2007 Bromley (Valproate) (Controls unexposed, sick), 2013 Arkilo (Valproate), 2015 Charlton (Valproate), 2017 Coste (Valproate) (Controls unexposed, NOS), 2020 Bjørk (Valproate) (Controls unexposed, sick), 2022
9
3.24
[
2.20
; 4.79]
10,785
3,173
not evaluable
ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk
Adab (Valproate), 2004 Viinikainen (Valproate) b, 2006 Cohen (Valproate), 2013 Veiby (Valproate) (Controls unexposed, sick) b, 2013 Bromley (Valproate) (Controls unexposed, sick), 2013 Bromley (Valproate), 2016 Huber-Mollema (Valproate), 2019 Wiggs (Valproate), 2020 Dreier (Valproate) (Epilepsy) (Controls unexposed, sick), 2023
9
1.48
[
1.23
; 1.78]
662
2,197
not evaluable
ASD (Autism spectrum disorder): Diagnosis
Adab (Valproate), 2004 Bromley (Valproate) (Controls unexposed, sick), 2013 Wood (Valproate), 2015 Huber-Mollema (Valproate), 2019 Coste (Valproate) (Controls unexposed, NOS), 2020 Wiggs (Valproate), 2020 Dreier (Valproate) (Epilepsy) (Controls unexposed, sick), 2023
7
2.77
[
2.19
; 3.50]
4,726
3,108
not evaluable
Psychomotor developmental disorders/delay
Koch (Valproate), 1996 Adab (Valproate), 2004 Viinikainen (Valproate) b, 2006 Thomas b (Valproate), 2008 Cohen (Valproate), 2011 Shallcross (Valproate), 2011 Bromley (Valproate) (Controls unexposed, sick), 2013 Deshmukh (Valproate), 2016 Videman (Valproate) (Controls unexposed, disease free), 2016
9
2.72
[
1.74
; 4.24]
82
343
not evaluable
Cognitive developmental disorders/delay (3-6 years old)
Gaily (Valproate) (Controls unexposed, sick), 2004 Cummings (Valproate) (Controls unexposed, disease free), 2011 Meador (Valproate), 2013 Deshmukh (Valproate), 2016 Kasradze (Valproate) (Controls unexposed, disease free), 2017 Coste (Valproate) (Controls unexposed, NOS), 2020
6
6.12
[
3.14
; 11.91]
3,466
1,170
not evaluable
ADHD (Attention deficit hyperactivity disorder): Diagnosis
Adab (Valproate), 2004 Bromley (Valproate) (Controls unexposed, sick), 2013 Cohen (Valproate), 2013 Huber-Mollema (Valproate), 2019 Wiggs (Valproate), 2020 Dreier (Valproate) (Epilepsy) (Controls unexposed, sick), 2023
6
1.54
[
1.27
; 1.86]
653
2,119
not evaluable
Cognitive developmental disorders/delay (< 3 years old)
Thomas b (Valproate), 2008 Bromley (Valproate) (Controls unexposed, sick), 2010 Shallcross (Valproate), 2011 Meador (Valproate), 2013 Videman (Valproate) (Controls unexposed, disease free), 2016
5
4.09
[
1.87
; 8.96]
103
190
not evaluable
Severe cognitive developmental delay (Mental retardation) (> 6 years old)
Gaily (Valproate) (Controls unexposed, disease free), 2004 Vinten (Valproate), 2005 Viinikainen (Valproate) b, 2006 Titze (Valproate) (Controls unexposed, sick), 2008 Meador (Valproate), 2013 Dreier (Valproate) (Epilepsy) (Controls unexposed, sick), 2023
6
2.81
[
2.06
; 3.82]
289
2,071
not evaluable
ADHD (Attention deficit hyperactivity disorder): Risk
Viinikainen (Valproate) b, 2006 Veiby (Valproate) (Controls unexposed, sick) b, 2013 Cohen (Valproate), 2013 Bromley (Valproate), 2016 Huber-Mollema (Valproate), 2019
5
1.15
[
0.68
; 1.96]
32
149
not evaluable
Severe cognitive developmental delay (Mental retardation) (3-6 years old)
Gaily (Valproate) (Controls unexposed, sick), 2004 Cummings (Valproate) (Controls unexposed, disease free), 2011 Meador (Valproate), 2013 Coste (Valproate) (Controls unexposed, NOS), 2020
4
5.02
[
3.12
; 8.08]
3,426
1,101
not evaluable
ASD (Autism spectrum disorder): Risk
Wood (Valproate), 2015 Bjørk (Valproate) (Controls unexposed, sick), 2018 Huber-Mollema (Valproate), 2019
3
1.28
[
0.48
; 3.42]
37
79
not evaluable
Learning disorders
Ren (Valproate) (Epilepsy), 2023
1
1.34
[
0.99
; 1.81]
-
172
not evaluable
Severe cognitive developmental delay (Mental retardation) (< 3 years old)
Meador (Valproate), 2013
1
3.29
[
1.00
; 10.85]
13
29
not evaluable
0.0
100.0
1.0